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Abstract 
The efficient, stable delivery of siRNA into cells, and the appropriate controls for non-specific off-target effects of 
siRNA are major limitations to functional studies using siRNA technology. To overcome these drawbacks, we 
have developed a single lentiviral vector that can concurrently deplete endogenous gene expression while ex-
pressing an epitope-tagged siRNA-resistant target gene in the same cell. To demonstrate the functional utility of 
this system, we performed RNAi-depleted Į-actinin-1 (Į-ACTN1) expression in human T cells. Į-ACTN1 RNAi 
resulted in inhibited chemotaxis to SDF-1Į, but it can be completely rescued by concurrent expression of 
RNAi-resistant Į-ACTN1 (rr-Į-ACTN1) in the same cell. The presence of a GFP tag on rr-Į-ACTN1 allowed for 
detection of appropriate subcellular localization of rr-Į-ACTN1. This system provides not only an internal control 
for RNAi off-target effects, but also the potential tool for rapid structure-function analyses and gene therapy. 
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Introduction 
Since the completion of human genome project, an 
emerging challenge is the development of tools for 
functional genomics. Small interfering RNA (siRNA) 
technology has proved to be a rapid and powerful tool 
in studying gene functions. However, siRNAs intro-
duced into cells via electroporation or liposomes 
cannot maintain stable under the regulation of target 
genes due to their progressive degradation or dilution 
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with cell division. Furthermore, some cell lines and 
many primary cells are very difficult to be transfected 
or nucleofected with siRNA. To overcome these 
drawbacks, several viral vectors capable of delivering 
a small hairpin RNA (shRNA) expression cassette 
into mammalian cells were developed. Among them, 
lentiviral vectors hold the most promise, as they are 
capable of infecting a broad spectrum of cell types, 
including non-dividing primary cells, and delivered 
exogenous DNA is integrated into the cell genome, 
which allows for sustained, stable expression in tis-
sues or cultured cells (1, 2). Thus, a lentiviral vec-
tor-based shRNA system could provide for a potential 
therapeutic tool for human diseases (3-5). 
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Although there are many guidelines and algorithms 
to predict accurate target sequence for siRNA gene 
knockdown (6, 7), the specificity of siRNA remains a 
problem. Accumulating evidence indicates that non-
specific off-target effects by siRNAs are prevalent. In 
various studies, dozens to hundreds of genes could be 
nonspecifically affected, by either the sense or an-
tisense strand of siRNAs (8-12). Alternatively, some 
siRNAs induce an interferon response (13). In con-
trast to siRNAs, shRNAs have a short hairpin loop 
that forms a closed end with a two-nucleotide over-
hang at the 3’ end. shRNAs may trigger off-target ef-
fects by being processed into siRNAs in vivo, by 
Dicer dependent or independent cleavage in the stem 
or loop, and changing them into an RNAi mechanism 
(14). Furthermore, shRNAs may also function as 
mimics of miRNAs to cause widespread off-target 
effects (15). These side-effects can lead to misinter-
pretation of phenotypes as a result of false-positive 
responses (9, 12, 16-18). To control for potential 
off-target effects of siRNA, various strategies have 
been employed, such as using multiple siRNAs di-
rected at differing regions in the mRNA, or restoring 
the expression of target gene with an RNAi-resistant 
mutant to demonstrate the reversal of phenotype (19). 
To address three major technical limitations in 
siRNA and shRNA application, including setting con-
trol for non-specific off-target effects of siRNA, en-
richment of shRNA-transduced cell population, and 
stable delivery of shRNA expression cassette into tar-
get cells, we developed a single lentiviral vector, 
which can concurrently knockdown and rescue ex-
pression of a target gene in the same cell. We demon-
strated the functional application of this system in T 
cells by shRNA-depleting endogenous Į-actinin-1 
(Į-ACTN1) while rescuing, concurrently, with green 
fluorescent protein (GFP)-tagged RNAi-resistant 
Į-ACTN1 (rr-Į-ACTN1). Using this approach, we 
found that Į-ACTN1 is specifically required for T cell 
chemotactic migration ҏҏinduced by efficient SDF-1Į. 
Results and Discussion 
As depicted in Figure 1A, the lentiviral vector was 
constructed with two long terminal repeats (LTRs) 
derived from pFG12 (2). The cis-regulatory sequences 
in the 3’ LTR was removed from the U3 region and 
copied to the 5’ LTR after reverse transcription, lead-
ing to transcriptional inactivation of both LTRs in 
target cells. One multiple cloning site (MCS) was cre-
ated for the insertion of shRNA expression cassette 
between the HIV flap sequence and the human ubiq-
uitin C (UbiC) promoter, while the other was created 
between GFP (or YFP) and UbiC promoter for ex-
pression of an RNAi-resistant gene or functionally 
related gene. The presence of GFP (or YFP) or GFP 
fusion peptide also allows for a determination of 
transduction efficiency. Since the GFP tag retards mi-
gration of the RNAi-resistant gene product on 
SDS-PAGE, one can readily distinguish it from the 
endogenous protein by Western blots using antibodies 
against the endogenous protein directly. It also allows 
for comparative quantification of exogenous 
RNAi-resistant product versus endogenous protein, 
and the extent of endogenous gene product depletion 
by shRNA. A further benefit of the GFP tag is to en-
sure that the RNAi-resistant protein is properly local-
ized within the cell, and to make it possible to analyze 
the functional effects of gene depletion at the sin-
gle-cell level, if necessary. Finally, the expression of a 
puromycin-resistance marker allows for removal of 
non-transduced cells, thereby enhancing the pheno-
type within a population of cells. 
In addition to a C-terminal GFP of the 
RNAi-resistant rescue proteins, we have also con-
structed vectors with C-terminal Flag-His6 (FH) 
(Figure 1A) that facilitate efficient and relatively 
clean immunoprecipitation (IF) of rescued genes in 
the presence of endogenous knockdown. With these 
new lentiviral vectors, we have transduced a variety 
of human and mouse cell types (e.g., epithelial cells, 
keratinocytes, fibroblasts, and hematopoietic cells), 
including tumor cell lines (e.g., HepG2, HaCAT, and 
Jurkat T cells) and primary cells (e.g., human primary 
endothelial cells, mouse embryonic fibroblasts, bone 
marrow derived macrophages, and hippocampal neu-
rons). The efficiency of transduction varies with cell 
type and virus titer applied, as expected; however, 
following puromycin selection of transduced Jurkat T 
cells, more than 98.5% of remaining cells were GFP 
positive (Figure 1B). 
To demonstrate the utility of the system, we chose 
to target Į-ACTN1 in human T cells. Į-actinins are  
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Figure 1  Multifunctional lentiviral vectors. A. Map of the lentivrial vectors. pFLRu was generated as described in Materials and 
Methods. There are two MCSs: 5’ of UbiC has the MCS for shRNA expression cassette, and 3’ of Ubic has the MCS for 
RNAi-resistant isoform of shRNA targeted gene containing an in-frame C-terminal GFP tag and FH. It also contains a puromycin 
(puro) resistance cassette. B. Jurkat T cells were infected with freshly produced lentivirus containing pFLRu-Į-ACTN1 shRNA, 
puromycin selected, and FACS analysis performed. The percentages of GFP positive cells are presented. Left panel: parental Jurkat T 
cells; right panel: lentiviral transduced Jurkat T cells. 
 
actin binding proteins cross-linking F-actin to actin 
bundles or network, also connecting F-actin to plasma 
membrane (20). There are four Į-actinin isoforms 
identified and characterized. Į-ACTN2 and 3 are 
muscle-specific, which crosslink F-actin in the region 
of Z-discs of striated muscle cells (21), while 
Į-ACTN1 and 4 are ubiquitously expressed. Increased 
cell motility in Į-ACTN4-deficient lymphocytes has 
been reported (22). However, the function of 
Į-ACTN1 on lymphocyte chemotactic migration re-
mains unknown. 
To obtain shRNA expression cassette, we per-
formed overlapping PCR to join U6 promoter with 
Į-ACTN1 shRNA target sequence, which produced a 
putative 27-mer shRNA shunting into a Dicer-dependent 
interference mechanism in vivo (14) (Figure 2A). 
Indeed, this predicted 27-mer shRNA exhibited much 
more potent protein depletion than a corresponding 
20-mer counterpart (Figure 2B and C).   
To rescue Į-ACTN1 knockdown, we synthesized 
an RNAi-resistant isoform of human Į-ACTN1 
(rr-Į-ACTN1). Four nucleotides in the siRNA target-
ing sequence were changed, and resulted in a new 
SspI restriction site that facilitated identification of 
correct transformants (Figure 3A). These nucleotide 
changes did not alter the encoded amino acids. En-
dogenous Į-ACTN1 level was dramatically reduced 
in Jurkat T cells infected with the lentivirus express-
ing the shRNA directed against human Į-ACTN1, 
while control shRNA expressing viruses had no effect 
(Figure 3B). Jurkat T cells were then infected with a 
lentivirus expressing both Į-ACTN1 shRNA and rr-Į- 
ACTN1-GFP. Endogenous Į-ACTN1 and rr-Į-ACTN1- 
GFP fusion proteins were detected by Western blots 
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Figure 2 Lentiviral-based Dicer-dependent Į-ACTN1 shRNA 
worked more potent than Dicer-independent counter part. A. 
Putative 27-mer shRNA for Į-ACTN1 and predicted shRNA 
cleavage sites are indicated in arrows. B. Putative 20-mer 
shRNA for Į-ACTN1. C. Western blot analysis of Jurkat T 
cells transduced with lentivirus expressing control shRNA 
(lane 1), Į-ACTN1 27-mer shRNA (lane 2), and Į-ACTN1 
20-mer shRNA (lane 3). Jurkat T cells were transduced by 
viruses carrying corresponding shRNA expression cassette, and 
selected by puromycin. The residue cells were collected, and 
the cell lysate was prepared for Western blots using 
anti-Į-ACTN1 antibody as primary antibody. 
 
using anti-Į-ACTN1 antibody (Figure 3B). Immu-
nostaining results showed that rr-Į-ACTN1-GFP was 
found to localize to the same subcellular site as en-
dogenous Į-ACTN1, and accumulate around the cell 
periphery, co-localizing with F-actin (Figure 3C). It 
indicated that the presence of the C-terminal GFP fu-
sion did not affect cellular localization of Į-ACTN1. 
Finally, we asked whether expression of rr-Į-ACTN1- 
GFP could rescue a phenotype caused by RNAi de-
pletion of endogenous Į-ACTN1 protein. RNAi de-
pletion of Į-ACTN1 in Jurkat T cells resulted in in-
hibited chemotaxis in response to an SDF-1Į stimulus 
(Figure 3D). This migratory/chemotactic phenotype 
was rescued by expression of rr-Į-ACTN1-GFP in the 
presence of endogenous Į-ACTN1 protein depletion 
(Figure 3D). Rescued cells expressed 3-fold more 
rr-Į-ACTN1-GFP than endogenous Į-ACTN1 (Figure 
3B), exhibiting enhanced migration relative to control 
shRNA infected cells (Figure 3D). These results 
showed that inhibition of T cell chemotaxis due to 
RNAi-mediated Į-ACTN1 depletion was specific, 
which is not the result of off-targeting, nonspecific 
gene silencing. 
Our system does not eliminate off-target effects of 
RNAi, but provides a reliable control for potential 
off-target effects. The two sets of cells expressing 
shRNA and shRNA with concurrent rescue have the 
same shRNA expression and loading in cells, there-
fore should have similar off-target effects. Our system 
also provides a tool to determine protein struc-
ture-function relationships in cells by rescuing shRNA 
depletion with RNAi-resistant mutant isoforms or 
specifically modified posttranslation. In addition, the 
status of the target protein in a specific signaling 
pathway can be determined by our system when res-
cuing with constitutively active isoforms of potential 
downstream effectors or upstream regulators. Fur-
thermore, our system could also be used for genetic 
modification of T cells or dendritic cells to target tu-
mors by knocking down immune suppression genes 
like A2A receptor (23) while concurrently expressing 
a tumor-specific targeting gene like TCR (24). 
Although we have successfully applied this system 
in different cell lines for functional studies, under 
some circumstances, especially in some of primary 
cells (e.g., bone marrow derived macrophages), we 
have encountered apoptotic, cytotoxic or osteoclasto-
genesis phenotypic changes, which cannot be rescued 
by expression of RNAi-resistant gene isoforms (data 
not shown). Nonspecific phenotypic changes could be 
the result of off-target effects of RNAi, or result from 
oversaturation of the endogenous small RNA pathway 
by shRNA overexpression (25, 26). If this is the case, 
we would recommend optimization of the shRNA 
sequence (25), or shRNA dosage, by replacing the U6 
promoter with an H1 promoter, which is a relative 
weak promoter (26, 27). 
The parental lentiviral vector described herein has 
been successfully used for germline transmission and 
in vivo analysis in mouse tissues (28). Indeed, we 
performed microinjection of concentrated lentivirus 
into the fetus or neonatal ventricle of the mouse brain 
and found significant expression of GFP in the neu-
rons, indicating a successful delivery of viral pack-
aged transcripts containing shRNA expression cas-
sette (data not shown). Therefore, this new system 
could also be applied in an in vivo setting or for a 
gene therapy, possibly, by knocking down both  
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Figure 3  Cellular and functional characterization of multifunctional lentivirus. A. Mutations in RNAi-targeted sequence of human 
Į-ACTN1 (red) to generate rr-Į-ACTN1. B. Western blot analysis. Į-ACTN1 levels in Jurkat T cells transduced with control shRNA 
lentivirus (lane 1), Į-ACTN1 shRNA lentivirus (lane 2), and Į-ACTN1 shRNA/rr-Į-ACTN1-GFP (lane 3) were detected using 
anti-Į-ACTN1 antibody. The Į-tubulin levels were detected as a loading control using anti Į-tubulin antibody. 30 μg of protein from 
each cell lysate was applied in each lane. C. Subcellular localization of endogenous Į-ACTN1 and rr-Į-ACTN1-GFP in Jurkat T cells 
transduced with control shRNA lentivirus (i-iii), Į-ACTN1 shRNA lentivirus (iv-vi), and Į-ACTN1 shRNA/rr-Į-ACTN1-GFP lenti-
virus (vii-ix). The lower panel (x-xii) demonstrates co-localization of rr-Į-ACTN1-GFP and F-actin. Cells were stained with the 
polyclonal antibody against GFP (i, iv, vii and x), the monoclonal antibody against Į-ACTN1 (ii, v and viii), or Rhodamine phal-
loidin (xi). Confocal images were obtained. D. Į-ACTN1 shRNA depletion of endogenous Į-ACTN1 in Jurkat T cells results in in-
hibited chemotaxis to SDF-1Į that is rescued by co-expression of rr-Į-ACTN1-GFP. Values represent average +/í standard deviation 
of triplicates. The experiments were performed three separate times with similar results. 
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disease mutation-derived transcripts and wild-type- 
allele-derived transcripts with an shRNA that targets 
both, and rescuing with RNAi-resistant wild-type 
protein or other therapeutic genes. This new system 
has the potential to advance basic research questions 
as well as development of gene-based therapeutics. 
Materials and Methods 
Antibodies and cell lines 
Monoclonal anti-Į-ACTN1 antibody was purchased 
from Sigma (A5044, clone BM-75.2) and used for 
Western blot and IF. Polyclonal antibody against GFP 
was purchased from Molecular Probes, and h-SDF-1Į 
was from PerproTech. Jurkat T cells were maintained 
in RPMI-10 containing 10% FBS, pen/strep and 
glutamine. Human keratinocyte cell line HaCat and 
large T antigen immortalized human bronchial epithe-
lial cell line Beas-2B, HEK-293-T cells were cultured 
in DMEM-10 containing 10% FBS, pen/strep and 
glutamine. 
Plasmid construction 
5’ LTR and 3’ LTRU3ǻ from FG12 (2) were sub-
cloned into pBluescript to obtain the intermediate 
vector (p1). PCR fragments of UbiC promoter, GFP 
(pEGFP-N1 as template), YFP (pCS2-YFP as tem-
plate), FH, and SV40-puro (pMX-puro as template) 
were spliced together in various combinations to ob-
tain another intermediate vector (p2). Digestion of p2 
with XhoI/NotI yielded a fragment containing 
UbiC-MCS-GFP (or YFP, FH)-SV40-puro that was 
then inserted between the LTRs in p1 to obtain the 
lentiviral vector shown in Figure 1. The complete 
vector was sequenced and named pFLRu (Feng’s 
Lenti-Rescue using UbiC promoter). An shRNA ex-
pression cassette was constructed by joint PCR. The 
predicted human Į-ACTN1 sequence targeted was 
GGGACACAGATCGAGAACATCGAAGAG. We 
obtained the hU6 promoter (f1) by amplifying 
pBS-hU6-1 template (2) with primers 1 and 2, and the 
shRNA fragment (f2) with primers 3 and 4 (Table 1). 
The last 5-6 base pairs are complementary to the cor-
responding base pairs before the hairpin in the same 
sequence. F1 was purified from 1% TAE-agrose gel 
with gel purification kit (Invitrogen) while f2 was 
purified from 12% TAE-polyacrylamide gel. Joint 
PCRs were carried out by using hU6 forward primer 
(primer 1), shRNA reverse primer (primer 4) and 
mixed template (2 μL of purified f1 and f2). The PCR 
products were purified, cut with XbaI/XhoI and sub-
cloned into the pFLRu. For control shRNA, we used a 
fire fly luciferase target sequence (5’- 
gCTTACGCTGAGTACTTCGA) under U6 promoter. 
Construction of rr-Į-ACTN1 cDNA 
Primers with three or four point mutations inside the 
siRNA targeted DNA sequence were designed, based 
upon wobble base pairing rules. For human Į-ACTN1, 
we designed four primers (primers 5-8) (Table 1). 
N-terminal fragment (N-ter) and C-terminal fragment 
(C-ter) of rr-Į-ACTN1 were obtained by PCR using 
primer pairs 5 and 6, or 7 and 8, respectively. Full 
length of rr-Į-ACTN1 was obtained by joint PCR us-
ing purified N-ter and C-ter mixed template and 
primers 5 and 8, followed by subcloning the fragment 
into EcoRI/AgeI sites of pFLRu. 
 
Table 1  PCR primer pairs used for hU6 promoter, shRNA fragment and human Į-ACTN1 cloning 
Primer Sequence Orientation 
1 5’-ACAGAATTCTAGAACCCCAGTGGAAAGACGCGCAG forward 
2 5’-GGTGTTTCGTCCTTTCCACAAG reverse 
3 5’-GTGGAAAGGACGAAACACCGGGACACAGATCGAGAACATCGAAGAGTTCAAGAGACTCTTC forward 
4 5’-TCCAGCTCGAGAAAAAGGGACACAGATCGAGAACATCGAAGAGTCTCTTGAACTCTTC reverse 
5 5’-AGAGAATTCCATGGACCATTATGATTCTCAGCAAAC forward 
6 5’-CCTCTTCAATATTTTCAATCTGTGTCCCCGCCTTCCGGAG reverse 
7 5’-CACAGATTGAAAATATTGAAGAGGACTTCCGGGATGGCCTG forward 
8 5’-CTCGGTACCGGTAGGTCACTCTCGCCGTACAGGCGCGTG reverse 
Note: Nucleotides in italics were hairpin sequence while in bold face were target RNAi sequence. 
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Lentiviral generation and transduction 
For lentivirus production, 8×105 of 293-T cells were 
played in each well of a 6-well plate overnight before 
transfection. For one well, the cells were transfected 
with packaging plasmids pHR’8.2'R/pCMV-VSV-G 
at a ratio of 8:1 (1.5 Pg total DNA) (kindly provided 
by Dr. Sheila Stewart, Washington University, St. 
Louis) and pFLRu plasmid (1.5 Pg). 24 h after trans-
fection, the cell culture medium was refreshed and the 
following day medium containing virus was harvested 
from transfected 293-T cells and filtered through a 
0.45 Pm filter to remove any residual 293-T cells. To 
infect target cells, virus was mixed with fresh medium 
and protamine sulfate (final 10 Pg/mL, Sigma), ap-
plied to target cells and incubated from 6 h to over-
night. Cells were then fed with fresh, virus-free me-
dium. 24 h later, puromycin was added (final 0.5 
Pg/mL) until all remaining cells were green under the 
fluorescent microscope. Dead Jurkat T cells were re-
moved by sedimentation through a Ficoll Paque 
(Sigma) layer. To avoid multi-entry of viral transcripts, 
we used the virus from one well of cell culture to in-
fect 1×106 Jurkat T cells, which gave about 50% in-
fected cells before selection. 
T cell migration assay 
Jurkat T cells (3×105/mL) were serum-starved in mi-
gration medium (RPMI containing 0.25% BSA and 10 
mM HEPES, pH 7.0) for 1.5 h. 4×105 cells in 100 PL 
of migration medium were loaded in the upper cham-
ber of uncoated transwell insert (5 Pm, Costar) in 
24-well plates, and 600 PL of migration medium in 
the lower chamber, with or without h-SDF-1Į (5 
ng/mL). All samples were performed in triplicate. Af-
ter 1.5 h at 37qC and 5% CO2 in incubator, cells in the 
lower chamber were collected, pelleted, resuspended 
in 100 PL of migration medium, and counted. 
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